Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Black Diamond Therapeutics Inc ONE MAIN STREET 14TH FLOOR CAMBRIDGE MA 02142 USA

www. blackdiamondtherapeutics.com Employees: 24 P: 617-252-0848

Sector:

Medical

Description:

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 131,042
Enterprise Value, $K 94,602
Shares Outstanding, K 56,975
Float, K 53,574
% Float 94.03%
Short Interest, K 4,133
Short Float 7.25%
Days to Cover 4.75
Short Volume Ratio 0.26
% of Insider Shareholders 5.97%
% of Institutional Shareholders 95.47%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -69,680 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -10,560 K
EBIT, $ 4,700 K
EBITDA, $ 5,040 K

Growth:

1-Year Return 0.22%
3-Year Return 12.75%
5-Year Return -91.79%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 92.53%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 11/06/25
Next Earnings Date 03/05/26 [--]
Earnings Per Share ttm 0.23
EPS Growth vs. Prev Qtr 21.05%
EPS Growth vs. Prev Year 46.43%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

BDTX Ratios

Ratio
Price/Earnings ttm 6.28
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 17.78%
Return-on-Assets % 13.80%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales 1.88
Price/Cash Flow N/A
Price/Book 1.02
Book Value/Share 2.33
Interest Coverage -1.54
60-Month Beta 3.36
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar